Testimonials

Veterinarians recommend it,
top riders and trainers rely on it

For over 30 years, Adequan® i.m. has been used by leading veterinarians, trainers and riders because of its proven ability to help improve joint function.1,2 Here are the reasons why they start with it and stay with it.

  • Reliable — the only FDA-Approved equine intramuscular polysulfated glycosaminoglycan2
  • Proven — backed by efficacy and safety studies reviewed by the FDA2
  • Trusted — millions of doses administered for equine patients3

INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Veterinarians

Adequan has survived the test of time. The only reason for that is its effect. It’s efficacious. It works. That’s why clients still request Adequan and that’s why I still recommend it.

Robert P. Boswell, DVM
Equine Sports Medicine Group

It’s frustrating that so many animals aren’t getting treated appropriately for the earlier stages of their joint disease. If we’re talking to clients about equine degenerative joint disease, I feel it’s an injustice not to inform them about Adequan. It’s the only FDA-approved PSGAG treatment to physically treat the disease process.

John J. Hanover, DVM
The Animal Hospital of Gurnee

I use Adequan to provide a quality FDA-approved medical product for my patients. It has proven to be reliable in the management of joint disease in our patient population. We have consistently used Adequan on all of our top athletes.

Rick Mitchell, DVM, MRCVS, Dipl. ACVSMR
Fairfield Equine Associates

When it comes to selecting healthcare products for my patients, I value reliability based on science and clinical observations, safety, and affordability. I’ve been recommending Adequan since it was introduced in the late 1980s, and I choose to stay with Adequan today because these qualities still hold true over 30 years later – now that is a solid track record!

Kathleen M. Anderson, DVM
Equine Veterinary Care, PC

Diagnosing horses with degenerative joint disease earlier is when we have the opportunity to make a difference. For us, a product that has i.m. administration and FDA-Approval behind it is an easy choice.

Kelly B. Tisher, DVM
Littleton Equine Medical Center

INDICATIONS Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.

Top Riders and Trainers

I want to help my horse in any way I can. Adequan has been a huge benefit to my horse, and that’s a wonderful thing to offer him. He’s an athlete; he works hard. In a tough sport like dressage, or being ridden on the trail as a retiree, I believe Adequan can help my horse.

Katie Jackson
U.S. Para-Equestrian, Dressage

But I think that's my responsibility to the horses. I hope that by making these smart decisions for them, when they are young enough, I can keep them healthy. I can help them with products like Adequan. In general, you have a much healthier, happier athlete who doesn't need to be laid up.

Laura Graves
U.S. Dressage Team; Olympic Medalist
Top 5 FEI Dressage World Ranking

I always do what's best for my horse. I really feel like Adequan has done such a great job in creating a product that keeps these horses going.

Kasey Perry-Glass
U.S. Dressage Team; Olympic Medalist
Top 10 FEI Dressage World Ranking

We try to do the best we can for the horse in every sort of situation. We started using Adequan at the recommendation of a veterinarian and because it has some real research behind it; just made common sense. We’ve had success with Adequan, so we keep doing what we’ve had success with.

Michael Matz, Distinguished Racehorse Trainer
Former Olympic Equestrian Team Member
Show Jumping Hall of Fame

I was introduced to Adequan, originally, as a therapeutic treatment for a horse with sore joints from DJD. I saw it made a big difference. There have been many cases where all I had to do was Adequan.

Adrienne Lyle
U.S. Dressage Team; Olympian

INDICATIONS Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.
1. McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse. St. Louis, MO: Elsevier, 2016; 33-48.
2. Adequan® i.m. Package Insert, Rev 1/19.
3. Data on file.

Let’s stay in touch

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

EQUINE VETERINARY
PROFESSIONAL 		HORSE OWNER
CONTACT INFORMATION
Contact Us Adverse Event Reporting Product Quality Complaints Sign Up
MORE ABOUT ADEQUAN
Dosing & Administration Prescribing Information Safety Information Ordering Information
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands
Animal Health Logo
All trademarks are the property of American Regent, Inc.
©2022, American Regent, Inc.
PP-AI-US-0268 (v4.0) 01/2022